Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed. Stereotactic ablative radiotherapy (SABR) can be a promising and ...

Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...

Individualized stereotactic ablative radiotherapy (SABR) based on lung tumor volume, location, and histology yielded high local control and low toxic effects, according to findings from a phase 2 ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown. Stereotactic ablative radiotherapy (SABR) has ...

SAN FRANCISCO, September 29, 2025 — A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage ...

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 This is an ...

In this exclusive MedPage Today video, Erminia Massarelli, MD, PhD, co-director of the lung cancer and thoracic oncology program at City of Hope in Duarte, California, discusses the results and ...

Results from a phase 2 trial suggest that neoadjuvant SAbR for RCC with IVC TT has immunogenic effects that reduce recurrence risk. Neoadjuvant stereotactic ablative radiation therapy (SAbR) to the ...

LONDON, ON – A new Phase I clinical trial from London Health Sciences Centre Research Institute (LHSCRI) has found high-precision radiation therapy is safe for use in patients with cancer that has ...

A new Phase I clinical trial from London Health Sciences Centre Research Institute (LHSCRI) has found high-precision radiation therapy is safe for use in patients with cancer that has spread to more ...